Volasertib Combined With Induction Chemotherapy in Acute Myeloid Leukemia
Status:
Withdrawn
Trial end date:
2017-02-01
Target enrollment:
Participant gender:
Summary
The study intervention involved in this study is the addition of a dose of volasertib as a
part of the initial chemotherapy regimen for AML.
The trial will involve a combination of the following drugs:
- Volasertib (the study drug)
- Idarubicin
- Cytarabine